Antifungal and Antibacterial Activities of Crude Extracts of Four Phellinus Species and Coltricia fragilissima (Agaricomycetes) from Cameroon and Democratic Republic of Congo.

Antifungal and antibacterial activities of crude extracts of Phellinus extensus, Ph. gilvus, Ph. pachyphloeus, Ph. senex and Coltricia fragilissima were investigated on eleven species of bacteria and three fungal human pathogens. The minimum inhibitory concentration (MIC) was determined by the microdilution method. The results of this study reveal that for the eleven strains of bacteria tested, including Bacillus subtilis, Enterococcus faecalis, Staphylococcus aureus, S. epidermidis, Enterobacter cloacae, Klebsiella aerogenes, Mycobacterium smegmatis, Proteus vulgaris, Proteus mirabilis and Escherichia choli, the MIC of the crude extract of the four species of Phellinus as well as that of C. fragilissima ranged from 3.13 to 12.50 mg/mL. For the three strains of fungi tested including Candida albicans, Aspergillus ochraceus and A. fumigetus, the MIC of the crude extracts of the same four species of Phellinus as well as that of C. fragilissima ranged from 0.39 to 3.13 mg/mL. These data reveal that the antimicrobial activity of crude extracts of Phellinus and Coltricia species is stronger on pathogenic fungi than on bacteria. C. fragilissima being of the same family as Phellinus and having recorded the values of MIC eminently close to those of the latter may potentially be used for medicinal purposes like the investigated Phellinus species. Being highly represented in the sub-Saharan regions and owing to the above-mentioned results, these species could now be considered as part of the non-exhaustive list of medicinal mushrooms in these regions and may constitute a new source of natural molecules that may be more active than synthetic products against certain fungal and bacterial borne diseases.

Comparative Assessment of Antifungal and Antibacterial Activities of Crude Extracts of the King Tuber Culinary-Medicinal Mushroom, Pleurotus tuber-regium (Agaricomycetes) from Cameroon.

Antifungal and antibacterial activities of crude extracts of carpophore compared with those of sclerotium of Pleurotus tuber-regium were investigated on 11 species of bacterial and 3 fungal human pathogens. The minimal inhibitory concentration (MIC) of carpophore extract was recorded to be 12.5 mg/mL on Bacillus subtilis, Enterococcus faecalis, Staphylococcus epidermidis, Escherichia cloacae, Proteus mirabilis, P. vulgaris, Klebsiella oxytoca, and K. aerogenes and 6.25 mg/mL on Staphylococcus aureus, Escherichia coli, and Mycobacterium smegmatis as well as on all three species of fungal pathogens including Candida albicans, Aspergillus fumigatus, and A. ochraceus. In comparison, the MIC of sclerotium was recorded to be 12.5 mg/mL on Bacillus subtilis and Klebsiella aerogenes; 6.25 mg/mL on Enterococcus faecalis, Staphylococcus aureus, S. epidermidis, Enterobacter cloacae, E. coli, Mycobacterium smegmatis, Proteus mirabilis, P. vulgaris, and Klebsiella oxytoca; and 3.13 mg/mL on the three fungal pathogens. Based on the abovementioned figures, it appears that strains of pathogenic fungi tested are much more sensitive to crude extracts than the abovementioned bacteria. In fact, antimicrobial activities of crude extracts of P. tuber-regium, no matter whether it is that of the carpophore or its sclerotium, are in general stronger on human pathogenic fungi than bacteria. These figures also demonstrate that crude extracts of sclerotium show a higher antimicrobial activity than that of carpophore. Carpophores and sclerotia of P. tuber-regium could therefore constitute a source of new molecules potentially more efficient than synthetic products against some human pathogenic fungi and bacteria.